[go: up one dir, main page]

DE2134179A1 - Prepns contg several bifidobacterium species - for normalizing intestinal flora - Google Patents

Prepns contg several bifidobacterium species - for normalizing intestinal flora

Info

Publication number
DE2134179A1
DE2134179A1 DE2134179A DE2134179A DE2134179A1 DE 2134179 A1 DE2134179 A1 DE 2134179A1 DE 2134179 A DE2134179 A DE 2134179A DE 2134179 A DE2134179 A DE 2134179A DE 2134179 A1 DE2134179 A1 DE 2134179A1
Authority
DE
Germany
Prior art keywords
germs
flora
intestinal
intestinal flora
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE2134179A
Other languages
German (de)
Inventor
Rolf Dr Schuler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE2134179A priority Critical patent/DE2134179A1/en
Publication of DE2134179A1 publication Critical patent/DE2134179A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1232—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt in powdered, granulated or dried solid form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Prepn. for the substitution of defective intestinal flora or for maintaining normal flora conditions, contg. several species of the genus Bifidobacterium as a mixt. For treating dysbiotic intestinal flora conditions, e.g. after antibiotic treatment. The prepn. can replace all the species (often up to 7) of Bifidobacteria which were originally present in the intestinal tract. The mixt. may be in fresh form or in carefully dried. The prepn. pref. also contains other essential intestinal germs, and an optimal nutrient substrate, pref. milk or whey with added growth activators, esp. yeast extract or yeast autolysate. The Bifidobacteria are pref. cultured as pure cultures and then mixed.

Description

"Bifidobakterien enthaltendes Präparat und Verfahren zur Herstellung desselben" Die Erfindung bezieht sich auf ein Bifidobakterien enthaltendes Präparat zur Substitution gestörter Darmfloren bzw. zur Aufrechterhaltung normaler Floraverhältnisse sowie auf ein Verfahren sur Herstellung dieses Präparates."Preparation containing bifidobacteria and process for production the same "The invention relates to a preparation containing bifidobacteria to replace disturbed intestinal flora or to maintain normal flora conditions as well as a process for the production of this preparation.

Es ist bekannt, daß unter der Vielzahl von Mikroorganismen, die den menschlichen Darmkanal besiedeln, bestimmte Bakteriengruppen, zum Beispiel Colikeime oder verschiedene Arten von Laktobasillen von besonderer Bedeutung sind.It is known that among the multitude of microorganisms which the colonize the human intestinal tract, certain groups of bacteria, for example coli germs or different types of lactobasils are of particular importance.

In neuerer Zeit konnte festgestellt werden, daß der menschliche Darmkanal zu etwa 40 % von Keimen der Bifidusgruppe und ru weiteren 40 % von keimen der Bacteroidesgruppe besiedelt ist. Dagegen beträgt der Anteil der aeroben Laktobasillen nur X nl 5 % der Gesamtkeimsahl und die coliformen Keime dürfen im Normalfall eine Gesamtkeimzahl von rund 1 % nicht übersteigen. Die prozentualen Restanteile entfallen auf zahlreiche andere Keimgruppen (Catenabakterien, Corynebakterion, Streptokokken u.a.), über deren physiologische Bedeutung bis Jetzt nichts bekannt ist.More recently it has been found that the human intestinal canal about 40% of germs of the bifidus group and another 40% of germs of the Bacteroides group is populated. In contrast, the proportion of aerobic lactobasils is only X nl 5% the total number of germs and the coliforms may normally have a total number of germs of around 1%. The remaining percentages are attributable to numerous other groups of germs (catenabacteria, corynebacteria, streptococci, etc.), over whose physiological significance is not yet known.

Alle bisher aufgefundenen Darmkeime, einschließlich der Colibakterien, sind als potentiell pathogene Keime anzusehen, das heißt, sie kannen sowohl im Dann selbst, sofern eine gestörte Darmflora vorliegt, als Krankheitserreger wirksam werden, sie können Jedoch auch außerhalb des Darmes auf Schleihhäuten oder in Wunden, Entzündungen oder Eiterungen hervorrufen.All intestinal germs found so far, including coli bacteria, are to be regarded as potentially pathogenic germs, that is, they can both in the then even if a disturbed one Intestinal flora is present as a pathogen They can be effective, however, also outside of the intestine on coarse membranes or cause inflammation or suppuration in wounds.

Die einzige, bisher bekannte Ausnahme in dieser Beziehung bilden die Keime der Bifidusgruppe. Diese sind von allen bisher im Darm aufgefundenen Mikroorganismen die einzigen wirklich apathogenen Keime. Vermutlich ist die Aufrechterhaltung normaler Floraverhältnisse in erster Linie dieser Kelingruppe zuzuschreiben. So ist es bekannt, daß mit Muttermilch ernährte Säuglinge eine praktisch reine Bifidusflora in ihrem Darm beherbergen und daß das Gedeihen dieser Säuglinge in einem direkten Zusammenhang mit dieser Bifidusflora steht.The only known exception in this respect are the Germs of the bifidus group. These are from all microorganisms previously found in the intestine the only really non-pathogenic germs. Presumably maintenance is more normal Flora conditions can be attributed primarily to this kelo group. So it is known that breast-fed infants have practically pure bifidus flora in theirs Gut accommodate and that the thriving of these infants is directly related with this bifidus flora.

Bifidobakterien richten durch ihr starkes Säuerungsvermögen in den oberen Darmabschnitten eine "Säureschranke" auf, welche es den in den tieferen Darmabschnitten siedelnden Fäulniserregern verwehrt, in höhere Darmabschnitte aufzusteigen, wo sie pathogen wirksam werden könnten.Bifidobacteria direct due to their strong acidity in the upper intestinal sections create an "acid barrier", which is present in the deeper intestinal sections colonizing putrefactive pathogens are prevented from ascending into higher intestinal sections, where they could be pathogenic.

Bifidobakterien bilden eine antibiotisch wirksame Substanz, die sich gegen gramnegative und auch gegen gewisse grampositive Keime richtet.Bifidobacteria form a substance that has an antibiotic effect directed against gram-negative and also against certain gram-positive germs.

Es ist schon versucht worden, die gestörten Darmflorcn (z.B.Attempts have already been made to remove the disturbed intestinal flora (e.g.

nach antibiotiabher Behandlung) dadurch wieder zu normalisieren, daß man lebende Bifiduskeime in entsprechend großer Menge suführte, in der Hoffnung, daß eine Ansiedelung dieser Keime im Darmtrakt möglich sei. Es hat sich Jedoch erwiesen, daß diese Bifiduskeime war als sogenaante passagere Keime den Darmtrakt durchwandern und in der Fäkalflora wiedersufinden sind, daß aber eine echte Ansiedelung dieser Keime nur in sehr wenigen Fällen gelingt. In der Regel verschwanden auch die in der Fähalflora nachweisbaren zugeführten Biiiduskeime bald nach dem Absetzen der entsprechenden Präparate.after antibiotic treatment) to normalize again that living bifidus germs were fed in correspondingly large quantities, in the hope that that a settlement of these germs in the intestinal tract is possible. However, it has been shown that these bifidus germs were passing through the intestinal tract as so-called transient germs and are found again in the faecal flora, but that there is a real settlement of these Germs only succeed in very few cases. Usually the in the fähalflora detectable supplied Biiidus germs soon after the weaning corresponding preparations.

Aufgabe der Erfindung irt es, ein Präparat zu schaffen, welches zur Behandlung sogenannter dysbiotischer Darmfloren geeignet ist und anhaltende Ansiedelung bzw. Neuanziedelung von humanen Btfidusarten im Darmtrakt bewirkt.The object of the invention irt it to create a preparation which for Treatment of so-called dysbiotic intestinal flora is suitable and sustained settlement or new settlement of human Btfidus species in the intestinal tract causes.

Es wurde festgestellt, daß die Bifidusflora Jeder Person sehr heterogen zusammengesetzt ist. Von den derzeit bekannten, rund 15 verschiedenen Arten von Bifidobakterien beherbergt Jeder Mensch in seinem Intestinaltrakt mehrere, oft bis zu 7 verschiedene Arten. Es hat sich als praktisch unmöglich erwiesen, eine andere Bifidusart als die bereits im Darmkanal vorhandenen Arten, anzusiedeln. Es ist Jedoch durchaus eine Ansiedelung einer oder mehrerer Arten möglich, die bei einer bestimmten Person bereits vorhanden sind, wenn auch (etwa durch antibiotische Schädigung) nur noch in sehr geringer und für die Aufrechterhaltung normaler Floraverhältnisse ungenügender Anzahl.It was found that the bifidus flora of every person is very heterogeneous is composed. Of the currently known, around 15 different types of Every person harbors several, often up to, bifidobacteria in their intestinal tract to 7 different types. It has proven practically impossible any other Bifidus species than the species already present in the intestinal canal. However, it is A settlement of one or more species is quite possible, with a certain Person already exist, even if only (e.g. due to antibiotic damage) still very little and inadequate for the maintenance of normal flora conditions Number.

Die bisher zur Behandlung von florabedingten Darmstörungen angewandten Präparate enthielten lediglich eine einzig.The previously used for the treatment of flora-related intestinal disorders Preparations contained only one.

Bifidusart. Es ist daher erklärlich, daß anhaltende therapeutische Erfolge mit solchen Präparaten nur bei Personen erreicht werden konnten, die eben diese eine Art in ihrem Darm beherbergten.Bifidus species. It is therefore understandable that persistent therapeutic Successes with such preparations could only be achieved with people who harbored this one species in their intestines.

Die vorstehend erläuterte Aufgabe wird dadurch gelöst, daß das erfindungsgemäße Präparat mehrere Arten der Gattung Bifidobakterien als Mischung enthält.The object explained above is achieved in that the inventive Preparation containing several species of the genus Bifidobacteria as a mixture.

Die Mischung kann in frischer Form verwendet werden, sie kann jedoch auch schonend getroclnet sein.The mixture can be used fresh, but it can also be gently dried.

Weiterhin kann die Mischung zusätzliche essentielle Keime der Darmflora sowie ein optimales Nährsubstrat enthalten.Furthermore, the mixture can contain additional essential germs of the intestinal flora as well as an optimal nutrient substrate.

Als NJhrsubstrat eignet sich Milch oder Molke, die mit einem Zusatz von Wachstumsaktivatoren versehen sein kann. Diese Wachstumsaktivatoren können Hefeextrakte oder Hefeautolysate sein.Milk or whey with an additive is suitable as a nutrient substrate can be provided by growth activators. These growth activators can be yeast extracts or yeast autolysates.

Das erfindungsgemäße Präparat kann dadurch hergestellt werden, daß mehrere Arten der Gattung Bitidobakterien als Reinkulturen für sich kultiviert und dann miteinander vermischt werden.The preparation according to the invention can be produced in that several species of the genus Bitidobacteria cultivated as pure cultures for themselves and then mixed together.

Die Mischung kann schonend getrocknet werden. Es können der Mischung auch andere exxentielle Keime der Darmflora ebenso wie ein optimales Nährsubstrat zugesetzt werden.The mixture can be gently dried. It can mix also other exxential germs of the intestinal flora as well as an optimal nutrient substrate can be added.

Die Keime der Darmflore können vor der Vermischung mit den verschiedenen Stämmen der 3ifidobakterien in dem Nährsubstrat selbst kultiviert werden. Als Nhhrsubstrat kann Milch oder Molke verwendet werden, der Wachstumsaktivatoren zugesetzt sein können. Als Wachstumsaktivatoren eignen sich z.B, Hefeextrakte oder Hefeautolysate.The germs of the intestinal flora can prevent mixing with the various Strains of the 3ifidobacteria are cultivated in the nutrient substrate itself. As a sewing substrate milk or whey can be used to which growth activators have been added can. Examples of suitable growth activators are yeast extracts or yeast autolysates.

Die Erfindung wird nachfolgend anhand von zwei Beispielen erläutert: Beispiel 11 Reinkulturen von Bifidobakterien, die t.B.The invention is explained below using two examples: Example 11 Pure cultures of bifidobacteria produced by t.B.

nach dem deutschen Patent 19 46 661 gewonnen wurden, werden in Milch mit einem Zusatz von Hefeextrakt oder Hefeautolysat weitergesüchtet, durch diese Weiterzüchtung aui ein beliebig großes Volumen vermehrt, sodann miteinander im gleichen Verhältnis, bezogen auf die Keimzahlen der Kulturen, vermischt. Dieses Gemisch eignet sich in frischer oder schonend getrockneter Form zur Behandlung gestörter Darmfloren. according to the German patent 19 46 661 are obtained in milk with the addition of yeast extract or yeast autolysate are further addicted by this Further breeding increased to an arbitrarily large volume, then with one another in the same way Ratio, based on the number of germs in the cultures, mixed. This mixture is suitable in fresh or gently dried form for the treatment of disturbed intestinal flora.

Beispiel 2) Reinkulturen von Bifidobakterien werden miteinander vermischt wie nach Beispiel 1. Nach der Vermischung dieser Kulturen miteinander kann diese Mischkultur entweder allein oder in Verbindung mit anderen Milchsäurebildern sur Herstellung von Milcherzeugnissen verwendet werden, die dann den gleichen Zwecken dienen können wie das nach Beispiel 1 gewonnene Präparat.Example 2) Pure cultures of bifidobacteria are mixed with one another as in Example 1. After these cultures have been mixed with one another, this can Mixed culture either alone or in conjunction with other lactic acid images sur Manufacture of dairy products are used, which then serve the same purposes can serve like the preparation obtained according to Example 1.

Das im Rahmen der Erfindung vorgesehene gleichzeitige Verabreichen von Bifidobakterien und einem für diese Keime optimalen Nährsubstrat schafft günstige Lebensbedingungen im Darmkanal, die für die erfolgreiche Ansiedelung der Bifidobakterien sehr förderlich ist.The simultaneous administration provided within the scope of the invention of bifidobacteria and an optimal nutrient substrate for these germs creates favorable Living conditions in the intestinal tract that are necessary for the successful settlement of the bifidobacteria is very beneficial.

P a t e n t a n s p r ü c h e P a t e n t a n s p r ü c h e

Claims (14)

P a t e n t a n s p r ü c h e 1.) Bifidobakterien enthaltendes Präparat zur Substitution gestörter Darmfloren bzw. zur Aufrechterhaltung normaler Floraverhältnisse' dadurch gekennzeichnet, daß es mehrere Arten der Gattung Bifidobakterium als Mischung enthält.P a t e n t a n s p r ü c h e 1.) Preparation containing bifidobacteria to replace disturbed intestinal flora or to maintain normal flora conditions' characterized in that there are several species of the genus Bifidobacterium as a mixture contains. 2.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es die Mischung in frischer Form enthält.2.) Preparation according to claim 1, characterized in that it is the mixture contains in fresh form. 3.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es die Mischung in schonend getrockneter Form enthält.3.) Preparation according to claim 1, characterized in that it is the mixture contains in gently dried form. 4.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es neben der Mischung andere essentielle Keime der Damflora enthält.4.) Preparation according to claim 1, characterized in that it is next to the mixture contains other essential germs of the dam flora. 5.) Präparat nach Anspruch 4, dadurch gekennzeichnet, daß es ein optionales Nährsubstrat enthält.5.) Preparation according to claim 4, characterized in that it is an optional Contains nutrient substrate. 6.) Präparat nach Anspruch 5, dadurch gekennzeichnet, daß als Nährsubstrat Milch oder Mo3Fke mit einem Zusats von Wachstumsaktivatoren vorgesehen ist.6.) Preparation according to claim 5, characterized in that as a nutrient substrate Milk or Mo3Fke with an addition of growth activators is provided. 7.) parat nach Anspruch 6, dadurch gekennzeichnet, daß als Wachstumsaktivatoren Hefeextrakte oder Hefeautolysate vorgesehen sind.7.) ready according to claim 6, characterized in that as growth activators Yeast extracts or yeast autolysates are provided. 8.) Verfahren zur Herstellung des Präparates nach einem oder mehreren der vorhergehenden Anspruche, dadurch gekennseichnet, daß mehrere Arten der Gattung Bifidobakterien als Reinkulturen kultiviert und dann miteinander vermischt werden.8.) Process for the preparation of the preparation according to one or more of the preceding claims, characterized in that several species of the genus Bifidobacteria are cultivated as pure cultures and then mixed with one another. 9.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß die Mischung schonend getrocknet wird.9.) The method according to claim 8, characterized in that the mixture is gently dried. 10.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß der Mischung andere essentielle Keime der Darmflora sugesetzt werden.10.) The method according to claim 8, characterized in that the mixture other essential germs of the intestinal flora are put in place. 11.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, d¢ der Mischung ein optimales Nährsubstrat zugesetzt wird.11.) The method according to claim 8, characterized in that d ¢ the mixture an optimal nutrient substrate is added. 12.) Verfahren nach den Ansprüche 10 und 11, dadurch gekennseichnet, daß die Keime der Darmflora vor der Beimischung in dem NUhrsubstrat kultiviert werden.12.) Method according to claims 10 and 11, characterized in that that the germs of the intestinal flora are cultivated in the nutrient substrate before admixture. 13.) Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß als Nährsubstrat Milch oder Molke mit einem Zusatz ton Wachatumsaktivatoren verwendet wird.13.) The method according to claim 11, characterized in that as a nutrient substrate Milk or whey with an addition ton of wax-date activators is used. 14.) Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß als Wachstumsaktivatoren Hefeextrakte oder Hefeautolysate verwendet werden.14.) The method according to claim 13, characterized in that as growth activators Yeast extracts or yeast autolysates can be used.
DE2134179A 1971-07-09 1971-07-09 Prepns contg several bifidobacterium species - for normalizing intestinal flora Pending DE2134179A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE2134179A DE2134179A1 (en) 1971-07-09 1971-07-09 Prepns contg several bifidobacterium species - for normalizing intestinal flora

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2134179A DE2134179A1 (en) 1971-07-09 1971-07-09 Prepns contg several bifidobacterium species - for normalizing intestinal flora

Publications (1)

Publication Number Publication Date
DE2134179A1 true DE2134179A1 (en) 1973-01-25

Family

ID=5813114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2134179A Pending DE2134179A1 (en) 1971-07-09 1971-07-09 Prepns contg several bifidobacterium species - for normalizing intestinal flora

Country Status (1)

Country Link
DE (1) DE2134179A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813733A1 (en) * 1977-03-31 1978-10-12 Yakult Honsha Kk PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
DE3125797A1 (en) * 1981-06-30 1983-01-13 Rudolf Dr. Schuler Dietetic agent
FR2560046A1 (en) * 1984-02-24 1985-08-30 Schuler Rudolf Dietetic product contg. bifidobacterium suis or infantis
EP0181170A3 (en) * 1984-11-05 1988-03-16 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Hypocholesterolemically active products
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
EP0482530A3 (en) * 1990-10-25 1993-03-31 Karl Heinz Hoelzel Composition for the regulation of intestinal flora
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813733A1 (en) * 1977-03-31 1978-10-12 Yakult Honsha Kk PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
DE3125797A1 (en) * 1981-06-30 1983-01-13 Rudolf Dr. Schuler Dietetic agent
FR2560046A1 (en) * 1984-02-24 1985-08-30 Schuler Rudolf Dietetic product contg. bifidobacterium suis or infantis
EP0181170A3 (en) * 1984-11-05 1988-03-16 Kabushiki Kaisya Advance Kaihatsu Kenkyujo Hypocholesterolemically active products
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US6645530B1 (en) 1988-08-02 2003-11-11 Gastro Services Pty Limited Treatment of gastro-intestinal disorders
EP0482530A3 (en) * 1990-10-25 1993-03-31 Karl Heinz Hoelzel Composition for the regulation of intestinal flora
US9623056B2 (en) 2000-07-20 2017-04-18 Crestovo Llc Probiotic recolonisation therapy
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9682108B2 (en) 2000-07-25 2017-06-20 Crestovo Llc Probiotic recolonisation therapy
US10369175B2 (en) 2000-07-25 2019-08-06 Crestovo Holdings Llc Probiotic recolonisation therapy
US9572841B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9610308B2 (en) 2000-07-25 2017-04-04 Crestovo Llc Probiotic recolonisation therapy
US9408872B2 (en) 2000-07-25 2016-08-09 Crestovo Llc Probiotic recolonisation therapy
US10772919B2 (en) 2000-07-25 2020-09-15 Crestovo Holdings Llc Probiotic recolonisation therapy
US9468658B2 (en) 2000-07-25 2016-10-18 Crestovo Llc Probiotic recolonisation therapy
US9737574B2 (en) 2000-07-25 2017-08-22 Crestovo Llc Probiotic recolonisation therapy
US9789140B2 (en) 2000-07-25 2017-10-17 Crestovo Holdings Llc Probiotic recolonisation therapy
US9867858B2 (en) 2000-07-25 2018-01-16 Crestovo Holdings Llc Probiotic recolonisation therapy
US9901604B2 (en) 2000-07-25 2018-02-27 Crestovo Holdings Llc Probiotic recolonisation therapy
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US9962414B2 (en) 2000-07-25 2018-05-08 Crestovo Holdings Llc Probiotic recolonisation therapy
US10617724B2 (en) 2010-08-04 2020-04-14 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en) 2010-08-04 2021-07-20 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en) 2010-08-04 2018-07-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en) 2010-08-04 2022-11-08 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en) 2010-08-04 2018-09-04 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11173183B2 (en) 2010-08-04 2021-11-16 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en) 2010-08-04 2022-11-22 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en) 2010-08-04 2021-09-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en) 2010-08-04 2019-05-07 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11541080B2 (en) 2010-08-04 2023-01-03 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en) 2010-08-04 2021-08-31 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en) 2010-08-04 2019-06-25 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en) 2010-08-04 2019-11-05 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en) 2010-08-04 2020-04-07 Crestovo Holdings, Inc. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en) 2010-08-04 2021-12-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en) 2010-08-04 2020-06-09 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en) 2010-08-04 2023-12-26 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10849937B2 (en) 2010-08-04 2020-12-01 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en) 2010-08-04 2020-12-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en) 2010-08-04 2021-04-27 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US11801269B2 (en) 2011-03-09 2023-10-31 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286011B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286012B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10251914B2 (en) 2011-03-09 2019-04-09 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US12295974B2 (en) 2011-03-09 2025-05-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10028980B2 (en) 2011-03-09 2018-07-24 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US12084727B2 (en) 2012-05-25 2024-09-10 Arizona Board Of Regents On Behalf Of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en) 2015-05-14 2021-09-21 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US10821138B2 (en) 2015-05-14 2020-11-03 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US12161678B2 (en) 2015-05-14 2024-12-10 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US12186349B2 (en) 2016-07-01 2025-01-07 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11071759B2 (en) 2016-08-03 2021-07-27 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US12390496B2 (en) 2016-08-03 2025-08-19 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US10561690B2 (en) 2016-08-03 2020-02-18 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11529375B2 (en) 2017-04-05 2022-12-20 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US12285447B2 (en) 2018-07-13 2025-04-29 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders

Similar Documents

Publication Publication Date Title
DE2134179A1 (en) Prepns contg several bifidobacterium species - for normalizing intestinal flora
DE69108846T2 (en) Whole foods made from hydrolyzed soluble fiber.
DE69227329T2 (en) Milk bacteria
DE2813733C2 (en)
DE69533593T2 (en) PREPARATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDER CONTAINING ARABINOGALACTAN AND POLYPHENOLS OF LARIX.
DE69827684T2 (en) New lactobacillus strains for the treatment of gastrointestinal disorders
DE2250993C2 (en) Antibacterial agent
DE60005104T2 (en) DIET ADDITIVE FROM FERMENTED MILK PRODUCTS FOR PREVENTING ÖSTEOPOROSIS
CH642517A5 (en) METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES.
CH665126A5 (en) DIETETARY AGENT FOR REDUCING THE UREA CONCENTRATION IN BODY LIQUIDS AND ITS PRODUCTION.
DE3120505C2 (en) Process for the production of solid sour milk products
DE69122186T2 (en) LACTOBACILLUS ACIDOPHILUS-F-133, PRODUCTION OF LACTIC ACID BACTERIA THEREOF AND METHOD FOR THE PRODUCTION THEREOF
CH650645A5 (en) DIET TABLE.
CH647945A5 (en) Lyophilised, enzymatically degraded sour milk product
DE1692313A1 (en) Process for making dairy products
DE1492779C3 (en) Process for the manufacture of sour milk products
EP0344786B1 (en) Inhibiting agent for clostridia
EP0184121B1 (en) Saccharose-containing, orally administered, foodstuffs, beverages, delicacies and pharmaceutical preparations
DE1019896B (en) Process for the production of milk products, such as sour milk or the like, with the addition of bacteria
DE2421066A1 (en) Bifido bacterial preparations - additionally contg. Lactobacillus casei var. rhamnosus
DE3147311C2 (en)
EP0515721A1 (en) Method for producing vegetable foodstuff with low nitrate content
DE2057906A1 (en) Preacidulated milk for infants - without the risk of acidosis
DE3509239A1 (en) Dietetic composition
DE2233551C3 (en) Process for the production of simulated human milk